Abstract: While conducting genomic surveillance (1,663 cases) from December 2020-April 2021 in Arizona, USA, we detected an emergent E484K-harboring variant, B.1.243.1.
Introduction: E484K variants have also been identified in reinfection cases, suggesting a role in breakthrough infections; these findings indicate the need to monitor for SARS-CoV-2 variants in real time.
Introduction: Genomic sequencing of SARS-CoV-2 E484K variant B.1.243.1, Arizona, USA.
Introduction: In contrast, the 2 additional B.1.243 cases bearing the E484K mutation alone were phylogenetically distinct from the B.1.243.1 clade, suggest
Figure: Emergence of E484K-harboring B.1.243.1 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Arizona, United States.
The in vitro and in vivo efficacy of CT-P59 against Gamma, Delta and its associated variants of SARS-CoV-2.
PMID: 34547629
2021
Biochemical and biophysical research communications
Introduction: In particular, three mutations (K417T, E484K, and N501Y) in RBD (Receptor Binding Domain) are common in Alpha (N501Y) and Beta (K417 N, E484K, and N501Y) which are associated with increased transmissibility, immune escape and pathogenicity.
Method: Mutant RBDs (K417T/E484K/N501Y, L452R/T478K, and L452R) were purchased from Sino Biological.
Method: Pseudoviruses for Gamma, Delta, Epsilon, Kappa, PMID: 34549975
2021
Journal of virology
Result: We assessed neutralization activity of sera against D614G pseudovirus (predominant variant in 2020), B.1.1.7, B.1.1.7+E484K, B.1.351-v1, B.1.351-v2, B.1.351-v3, P.1, B.1.617.2-v1, B.1.617.2-v2, B.1.525, B.1.526, B.1.617.1-v1, B.1.617.1-v2, C.37-v1, C.37-v2, B.1.427/B.1.429, B.1.621, A.23.1-v1, A.23.1-v2, and A.VOI.V2 (Table 1).
Result: mRNA-1273-elicited neutralization titers against B.1.1.7, B.1.1.7+E484K, B.1.427/B.1.429, P.1, and B.1.351-v1 observed herein corroborated previous findings.
Table: E484K
Figure: Data for B.1.1.7 (Alpha), B.1.1.7+E484K (Alpha), P.1 (Gamma), and B.1.427/B.1.429 were published previously.
Figure: The pseudoviruses tested incorporated D614G or the spike substitutions present in B.1.1.7
SARS-CoV-2 B.1.1.7 lineage rapidly spreads and replaces R.1 lineage in Japan: Serial and stationary observation in a community.
PMID: 34560289
2021
Infection, genetics and evolution
Abstract: After the emerging of the R.1 lineage harboring E484K variant (designated VOI in Japan), the prevalent B.1.1.214 lineage were no longer identified.
Introduction: We previously reported on the SARS-CoV-2 R.1 lineage harboring spike W152L, E484K and G769V mutations.
Table: E484K
Discussion: The R.1 carries the W152L N-terminal domain and E484K in receptor binding domain, which have been shown to be of concern for immune escape, while there are no reports on its transmission potential.
Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients.
PMID: 34561414
2021
Signal transduction and targeted therapy
Discussion: The K417N+E484K+N501Y triple mutant in the B.1.351 variant significantly reduces the neutralizing activity of convalescent and post-vaccination sera.
E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: Binding free energy calculation studies.
PMID: 34562851
2021
Journal of molecular graphics & modelling
Introduction: In addition, for most of the studied neutralizing antibodies and nanobodies, the E484K mutation leads to reduced binding affinities between RBD and these antibodies/nanobodies mainly due to the mutation-caused disadvantage electrostatic interactions, which weakens the effectiveness of these antibodies and even evades the immune protect.
Introduction: In th
Introduction: In the 501Y.V2 and 501Y.V3 variants, besides the N501Y mutation, two other mutations E484K and K417N (or K417T) occurred in RBD of the S protein, and it was revealed that the E484K mutation obviously enhances the binding affinity between RBD and hACE2.
Mutations of SARS-CoV-2 RBD May Alter Its Molecular Structure to Improve Its Infection Efficiency.
Conclusion: Mutations in N501Y, N439K, and E484K RBDs showed insignificant changes in flexibility.
Conclusion: We identified that the essential motion of E484K, N439K, S477N, and L452R RBDs were mainly in the loop Y473-C489, which is located at the binding interface with ACE2 receptor.
Result: Additionally, S477N and L452R showed different loop conformers at loop 457-467 (a flexible loop) of RBM, while N501Y, E484K, and N439K showed similar conformers in the same region during the
Antibody-Mediated Neutralization of Authentic SARS-CoV-2 B.1.617 Variants Harboring L452R and T478K/E484Q.
Introduction: In Kappa, but not Delta, E484 is substituted with a Glutamine (Q) and might confer immune escape similar to E484K.
Introduction: It has been shown that
Discussion: Hence, both substitutions E484K and E484Q might limit the sensitivity of SARS-CoV-2 to neutralizing antibodies.
Discussion: Imdevimab, classified as a class 3 antibody, binds outside the ACE2-binding site matching the here observed high sensitivity to Kappa and efficient neutralizing of E484K carrying variants Beta and Gamma, as documented recently.
Discussion: In this work, we detected a lower capacity of convalescent or vaccine-elicited sera to neutralize the E484Q-carrying variant Kappa matching the previously shown reduced neutralization of variants Beta and Zeta carrying E484K.
Clinical Characterization and Genomic Analysis of Samples from COVID-19 Breakthrough Infections during the Second Wave among the Various States of India.
Discussion: K417N, E484K, L452R, and E484Q are the mutations known to disrupt receptor-binding domain (RBD) binding capacity, making them more infectious by immune escape against the current vaccines.
Emergence and Spread of a B.1.1.28-Derived P.6 Lineage with Q675H and Q677H Spike Mutations in Uruguay.
Introduction: The VOC P.1, which harbors the mutations of concern S: Introduction: The lineage P.3 (former VOI Theta) emerged in the Philippines, and it includes substitutions S:E484K/N501Y/P681H among the lineage-defining mutations; the first sample was collected on 8 January 2021, and later it further spread to the USA, Germany, and Malaysia, among other countries.
Introduction: The lineages P.2, P.4, and P.5, carrying the concerning amino acid changes S:E484K, S:L452R, and S:E484Q/N501T, respectively, were also initially detected in samples from Brazil.
SARS_CoV_2 mutation literature information.
PMID: 
2021
Emerging infectious diseases
Browser Board
Co-occurred Entities
Filtrator
ViMRT